Patients with metastatic breast cancer may show tumor cells in the blood stream. Detection of these circulating tumor cells may affect overall survival of patients with breast cancer. This assay is useful as an aid in the monitoring of patients with metastatic breast cancer. Positive results predict shorter progression free survival. Patients on Doxorubicin (Adriamycin) must give a gap of minimum 7 days prior to blood sampling.